文献速递治疗药物监测与药物基因组学特殊人群用药

阿帕替尼在成人癌症患者中的群体药代动力学与药物遗传学研究

Population pharmacokinetics and pharmacogenetics of apatinib in adult cancer patients.
PubMed 文献 · Br J Clin Pharmacol · 2023-02-03

本研究在成人癌症患者中建立阿帕替尼群体药代动力学模型,并基于蒙特卡洛模拟优化给药方案。CYP3A5基因型与系统癌症类型是药代动力学参数最显著的协变量;不表达CYP3A5*1的患者所需阿帕替尼剂量应比CYP3A5*1表达者高33.33%–50.00%。

要点

  • CYP3A5*1表达者(*1/*1和*1/*3)的阿帕替尼表观清除率和表观分布容积低于不表达者(*3/*3)。
  • 非消化系统癌症患者的表观分布容积和吸收速率常数高于消化系统癌症患者。
  • 不表达CYP3A5*1的患者阿帕替尼剂量应比CYP3A5*1表达者高33.33%–50.00%。

核心结论

  • CYP3A5基因型和系统癌症类型对阿帕替尼药代动力学参数有共同影响。

研究设计与样本

  • 纳入接受阿帕替尼治疗的多种类型癌症成人患者,用HPLC-MS/MS测定血浆阿帕替尼浓度,用TaqMan等位基因判别技术测定CYP3A5基因型,用NONMEM V7.4建立群体药代动力学模型,并基于蒙特卡洛模拟优化给药方案。

主要发现

  • CYP3A5基因型和系统癌症类型(消化系统癌症与非消化系统癌症)是药代动力学参数最显著的协变量。
  • CYP3A5*1表达者(CYP3A5*1/*1和CYP3A5*1/*3)的表观清除率和表观分布容积低于不表达CYP3A5*1者(CYP3A5*3/*3)。
  • 非消化系统癌症患者的表观分布容积和吸收速率常数高于消化系统癌症患者。

关键数值与推荐

  • 剂量模拟结果显示,不表达CYP3A5*1的患者阿帕替尼剂量应比CYP3A5*1表达者高33.33%–50.00%。

临床怎么用

  • 临床可参考CYP3A5基因型(是否表达CYP3A5*1)与癌症类型(消化系统与非消化系统)评估阿帕替尼个体化给药剂量。
  • 对不表达CYP3A5*1的成人癌症患者,可考虑比CYP3A5*1表达者使用高33.33%–50.00%的阿帕替尼剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Apatinib is widely used in Chinese cancer patients. As the in vivo drug disposition of apatinib has large individual differences, adverse events are prone to occur. Cytochrome P450 (CYP)3A5 and cancer types maybe the main factors affecting this individual differences. The objective of our study was to establish a population pharmacokinetics (PK) model of apatinib in adult cancer patients, and to explore optimal dosage regimens for individualized treatment. METHODS: Adult patients with various types of cancer treated with apatinib were enrolled. The concentration of apatinib in plasma was determined by high-performance liquid chromatography-tandem mass spectrometry. CYP3A5 genotype was determined using TaqMan allelic discrimination technique. The population PK model was developed by NONMEM V7.4. The dosing regimen was optimized based on Monte Carlo simulations. RESULTS: A population PK model of apatinib in adult cancer patient was established. CYP3A5 genotype and systemic cancer type (digestive system cancers, nondigestive system cancers) were the most significant covariates for PK parameters. Patients with CYP3A5*1 expressers (CYP3A5*1/*1 and CYP3A5*1/*3) had lower apparent clearance and apparent volume of distribution than patients who do not express CYP3A5*1 (CYP3A5*3/*3). Patients with nondigestive system cancer had higher apparent volume of distribution and absorption rate constant than digestive system cancer. The results of dose simulation suggest that the apatinib dose in patients who do not express CYP3A5*1 should be 33.33-50.00% higher than that in CYP3A5*1 expressers. CONCLUSIONS: A population PK model of apatinib in adult cancer patients was established. CYP3A5 genotype and systemic cancer type had concurrent effects on PK parameters. CYP3A5 patients who do not express CYP3A5*1 required higher doses.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Yang XM, Ye PP, Liu XL, et al. Population pharmacokinetics and pharmacogenetics of apatinib in adult cancer patients. Br J Clin Pharmacol. 2023. PMID: 36662574. doi:10.1111/bcp.15665

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。